Infinity Pharma Reports Phase 1 Results On Oral Hedgehog Inhibitor IPI-926

Over the weekend, Infinity Pharmaceuticals INFI presented initial Phase I data on oral hedgehog inhibitor IPI-926 at the European Society for Medical Oncology meeting in Milan. With i.v. Hsp-90 inhibitor IPI-504 all but dead, Infinity is focusing clinical resources on IPI-926, oral Hsp-90 inhibitor IPI-493 and preclinical PI3K inhibitors from Intellikine. Risks for INFI are typical with other drug discovery companies. IPI-504 may fail in the clinic and Infinity may not file new INDs. Piper remains Neutral until it sees clinical progress and validation. INFI closed Friday at $5.68
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsBiotechnologyHealth CarePiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!